Lilly to Acquire Diabetes Cell Therapy Partner Sigilon for US$35 M Upfront
By Lucy Haggerty
Pharma Deals Review: Vol 2023 Issue 7 (Table of Contents)
Published: 8 Jul-2023
DOI: 10.3833/pdr.v2023.i7.2795 ISSN: 1756-7874
Section: Mergers & Acquisitions
Fulltext:
Abstract
Building upon its existing expertise in the diabetes space, Eli Lilly has agreed to acquire Sigilon Therapeutics for approximately US$34...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS